Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Board Authorizes $22.75M Share Buyback

NEW YORK (GenomeWeb News) – Luminex's board of directors has authorized the company to repurchase up to the lesser of $22.75 million worth of its common stock or 650,000 shares, the firm said in a document filed today with the US Securities and Exchange Commission.

In the filing, the Austin, Texas-based firm said that it may repurchase its stock in the open market from time to time or in privately negotiated transactions.

The firm's board had authorized a share buyback program in November 2010 for $21 million.

Luminex is scheduled to release its fourth-quarter and full-year 2011 earnings on Feb. 6. As of Sept. 30, 2011, it had $65.1 million in cash and cash equivalents and $31.6 million in short-term investments.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.